

Federico Cappuzzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5408729/publications.pdf>

Version: 2024-02-01

293
papers

37,014
citations

11908

72
h-index

3688

186
g-index

306
all docs

306
docs citations

306
times ranked

32361
citing authors

#	ARTICLE	IF	CITATIONS
1	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , 2022, 17, 309-323.	0.5	114
2	Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 7-18.	1.6	57
3	Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. , 2022, 10, e003027.		45
4	KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously". <i>Journal of Thoracic Oncology</i> , 2022, 17, e40-e41.	0.5	1
5	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	0.8	7
6	A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting. <i>Cancers</i> , 2022, 14, 2971.	1.7	6
7	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103176.	2.0	11
8	COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience. <i>Breast Journal</i> , 2021, 27, 359-362.	0.4	5
9	Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma. <i>Oral Oncology</i> , 2021, 115, 105133.	0.8	1
10	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1525.	1.0	16
11	The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 669839.	1.3	4
12	IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1909-1924.	0.5	212
13	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2065-2077.	0.5	28
14	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3713-3736.	1.3	12
15	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1547-1558.	0.5	108
16	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1438-1447.	5.1	45
17	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
18	ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , 2020, 21, 15-20.	1.1	58

#	ARTICLE	IF	CITATIONS
19	Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. <i>Clinical and Translational Oncology</i> , 2020, 22, 294-301.	1.2	4
20	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020, 12, 2948.	1.7	14
21	A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens. <i>Cancer Cytopathology</i> , 2020, 128, 928-938.	1.4	13
22	Blockage of interleukin-1 β with canakinumab in patients with Covid-19. <i>Scientific Reports</i> , 2020, 10, 21775.	1.6	58
23	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2020, 31, S1078.	0.6	2
24	1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. <i>Annals of Oncology</i> , 2020, 31, S814-S815.	0.6	8
25	1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations. <i>Annals of Oncology</i> , 2020, 31, S817-S818.	0.6	14
26	1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations. <i>Annals of Oncology</i> , 2020, 31, S837-S838.	0.6	14
27	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	2.0	60
28	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	1.1	50
29	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 565-576.	1.0	9
30	Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?. <i>Journal of Thoracic Oncology</i> , 2020, 15, e92-e93.	0.5	0
31	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. <i>Radiotherapy and Oncology</i> , 2020, 149, 84-88.	0.3	13
32	Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1351-1360.	0.5	379
33	Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. <i>Anticancer Research</i> , 2020, 40, 983-990.	0.5	17
34	Crizotinib in ROS1 and MET Deregulated NSCLC Response. <i>Clinical Cancer Research</i> , 2020, 26, 1775-1775.	3.2	2
35	How selecting best upfront therapy for metastatic disease? Focus on ROS1-rearranged disease. <i>Translational Lung Cancer Research</i> , 2020, 9, 2686-2695.	1.3	6
36	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , 2020, 16, 1433-1439.	1.1	14

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	1.3	70
38	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019, 105, 3-14.	0.6	9
39	Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFOST trial. <i>Annals of Oncology</i> , 2019, 30, v609-v610.	0.6	7
40	ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. <i>Annals of Oncology</i> , 2019, 30, v658.	0.6	2
41	Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial. <i>Annals of Oncology</i> , 2019, 30, v659-v660.	0.6	0
42	Crizotinib in <i>MET</i> -Deregulated or <i>ROS1</i> -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7312-7319.	3.2	139
43	Chemoimmunotherapy for stage IV non-small-cell lung cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e467.	5.1	0
44	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. <i>Cancers</i> , 2019, 11, 1431.	1.7	7
45	The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 429-449.	1.3	54
46	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.3	24
47	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 924-937.	5.1	1,133
48	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 135, 74-77.	0.3	14
49	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
50	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 387-401.	5.2	704
51	Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. <i>Oncotarget</i> , 2019, 10, 561-572.	0.8	15
52	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019, 24, e1165-e1171.	1.9	35
53	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102
54	P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S563-S564.	0.5	0

#	ARTICLE	IF	CITATIONS
55	P1.14-03 Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFIROST Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, S553.	0.5	1
56	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 35-40.	0.9	122
57	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. <i>British Journal of Cancer</i> , 2019, 120, 57-62.	2.9	68
58	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , 2019, 20, e186-e194.	1.1	40
59	ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9121-TPS9121.	0.8	1
60	The interplay between PD-L1 and vimentin in NSCLC patients: An exploratory analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20688-e20688.	0.8	0
61	Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC. , 2019, , .		0
62	<i>HER2</i> Deregulation in Lung Cancer: Right Time to Adopt an Orphan?. <i>Clinical Cancer Research</i> , 2018, 24, 2470-2472.	3.2	5
63	Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. <i>Future Oncology</i> , 2018, 14, 1477-1486.	1.1	14
64	Exposureâ€“response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 77-86.	1.1	18
65	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. <i>Journal of Thoracic Disease</i> , 2018, 10, 3909-3921.	0.6	35
66	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2018, 9, 17554-17563.	0.8	21
67	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2251-2258.	0.8	308
68	How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. <i>Journal of Thoracic Disease</i> , 2018, 10, 3883-3890.	0.6	2
69	PC07.04 Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - Chemo + IO. <i>Journal of Thoracic Oncology</i> , 2018, 13, S247-S248.	0.5	0
70	Multicentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. <i>Annals of Oncology</i> , 2018, 29, viii644.	0.6	0
71	P1.01-15 ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, S464-S465.	0.5	0
72	Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. <i>Tumor Biology</i> , 2018, 40, 101042831881504.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018, 100, 126-134.	1.3	83
74	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018, 378, 2288-2301.	13.9	2,808
75	Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. <i>Journal of Clinical Oncology</i> , 2018, 36, 9002-9002.	0.8	78
76	IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA9000-LBA9000.	0.8	153
77	Lung Cancer Update 2017: from the test tube to the bed. <i>Annals of Translational Medicine</i> , 2018, 6, 86-86.	0.7	0
78	Atezolizumab: state of art and future perspective in non-small cell lung cancer treatment. <i>Translational Cancer Research</i> , 2018, 7, S549-S552.	0.4	0
79	The neuropilin 2 isoform NRP2b uniquely supports TGF β 2-mediated progression in lung cancer. <i>Science Signaling</i> , 2017, 10, .	1.6	41
80	P2.06-016 Phase 2 Study of Ramucirumab plus Weekly Docetaxel in Stage IV NSCLC Following Progression after Platinum-Based Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1079-S1080.	0.5	0
81	MTE26.02 EGFR Targeted Therapies: Lessons Learned. <i>Journal of Thoracic Oncology</i> , 2017, 12, S177-S178.	0.5	0
82	P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1296-S1297.	0.5	4
83	P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1336-S1337.	0.5	2
84	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 181-187.	0.9	40
85	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 15-26.	0.5	299
86	PUB076 Programmed Cell Death Ligand 1 and Neutrophil to Lymphocyte Ratio to Predict Response to Nivolumab in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2390-S2391.	0.5	1
87	Treating & EGFR mutation resistance in non-small cell lung cancer role of osimertinib. <i>The Application of Clinical Genetics</i> , 2017, Volume 10, 49-56.	1.4	25
88	A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay. <i>Journal of Thoracic Disease</i> , 2017, 9, 2311-2314.	0.6	0
89	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017, 6, 373-386.	1.3	45
90	Abstract CT126: Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063. <i>Cancer Research</i> , 2017, 77, CT126-CT126.	0.4	3

#	ARTICLE	IF	CITATIONS
91	MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations.. Journal of Clinical Oncology, 2017, 35, e20656-e20656.	0.8	1
92	Contribution of <i>KRAS</i> mutations and c.2369C > T (p.T790M) <i>EGFR</i> to acquired resistance to EGFR-TKIs in <i>EGFR</i> mutant NSCLC: a study on circulating tumor DNA. Oncotarget, 2017, 8, 13611-13619.	0.8	81
93	Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.. Journal of Clinical Oncology, 2017, 35, e20676-e20676.	0.8	1
94	Abstract 4853: NRP2b, a unique isoform of NRP2, promotes aggressive lung cancer phenotypes. , 2017, , .		0
95	Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. Journal of Thoracic Disease, 2016, 8, E1348-E1350.	0.6	6
96	Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. Translational Lung Cancer Research, 2016, 5, 579-587.	1.3	7
97	Minimizing Aircraft ECS Bleed Off-Take - Virtual Integrated Aircraft Applications. SAE International Journal of Aerospace, 2016, 9, 151-162.	4.0	3
98	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2016, 99, 31-37.	0.9	31
99	PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program. Journal of Thoracic Oncology, 2016, 11, S302-S303.	0.5	5
100	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i> -Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Journal of Clinical Oncology, 2016, 34, 2858-2865.	0.8	216
101	cMET Exon 14 Skipping: From the Structure to the Clinic. Journal of Thoracic Oncology, 2016, 11, 1423-1432.	0.5	51
102	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Annals of Oncology, 2016, 27, 1291-1298.	0.6	129
103	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. Drugs, 2016, 76, 831-840.	4.9	13
104	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports, 2016, 36, 1166-1172.	1.2	15
105	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2016, 8, 176-187.	1.4	25
106	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer, 2016, 93, 95-103.	0.9	41
107	Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2016, 9, 203-214.	1.3	6
108	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. Journal of Thoracic Oncology, 2016, 11, 545-555.	0.5	87

#	ARTICLE	IF	CITATIONS
109	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. <i>Annals of Oncology</i> , 2016, 27, 281-286.	0.6	254
110	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. <i>ESMO Open</i> , 2016, 1, e000118.	2.0	6
111	Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9079-9079.	0.8	4
112	Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9103-TPS9103.	0.8	1
113	cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. <i>Cancers</i> , 2015, 7, 556-573.	1.7	33
114	Experience with erlotinib in the treatment of non-small cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 146-163.	1.0	25
115	The role of research nurse in translational studies: LUCAS experience. <i>Annals of Oncology</i> , 2015, 26, vi113.	0.6	0
116	microRNA classifiers are powerful diagnostic/prognostic tools in <i>ALK</i> , <i>EGFR</i> , and <i>KRAS</i> -driven lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14924-14929.	3.3	74
117	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. <i>Lung Cancer</i> , 2015, 87, 89-95.	0.9	40
118	Nit-Picking around second line in EGFR NSCLC: just an academic effort. <i>Annals of Oncology</i> , 2015, 26, 448-450.	0.6	0
119	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2015, 16, 257-265.	5.1	1,269
120	Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. <i>PLoS ONE</i> , 2015, 10, e0125037.	1.1	9
121	Onartuzumab in lung cancer: the fall of Icarus?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 487-489.	1.1	32
122	Crizotinib Therapy for Advanced Lung Adenocarcinoma and a <i>ROS1</i> Rearrangement: Results From the EUROS1 Cohort. <i>Journal of Clinical Oncology</i> , 2015, 33, 992-999.	0.8	326
123	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 665-672.	0.5	28
124	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015, 64, 921-928.	6.1	22
125	Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and) <i>TJ ETQq1 1 0.784314 rgBT/Overlo</i>	0.4	16
126	Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. <i>Drugs and Aging</i> , 2015, 32, 907-916.	1.3	9

#	ARTICLE	IF	CITATIONS
127	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British Journal of Cancer, 2015, 112, 95-102.	2.9	515
128	Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8101-8101.	0.8	4
129	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. Translational Lung Cancer Research, 2015, 4, 465-74.	1.3	21
130	Resistance to anti-angiogenic drugs and therapeutic options. , 2015, , 61-66.		0
131	Overcoming EGFR-TKI Resistance. , 2015, , 37-50.		0
132	Resistance to EGFR TKIs. , 2015, , 27-36.		0
133	Therapy options for advanced NSCLC. , 2015, , 5-25.		0
134	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.. Journal of Clinical Oncology, 2015, 33, 11076-11076.	0.8	0
135	Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. Annals of Translational Medicine, 2015, 3, 32.	0.7	0
136	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2014, 5, 43.	1.3	1
137	Management of NSCLC: focus on crizotinib. Expert Opinion on Pharmacotherapy, 2014, 15, 2587-2597.	0.9	15
138	<i>HER2</i> in solid tumors: more than 10 years under the microscope; where are we now?. Future Oncology, 2014, 10, 1469-1486.	1.1	39
139	First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer. New England Journal of Medicine, 2014, 371, 2167-2177.	13.9	2,808
140	<i>ALK</i>Rearrangement in a Large Series of Consecutive Non-“Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. Archives of Pathology and Laboratory Medicine, 2014, 138, 1449-1458.	1.2	93
141	Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opinion on Pharmacotherapy, 2014, 15, 2293-2305.	0.9	16
142	MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. Clinical Colorectal Cancer, 2014, 13, 37-45.e4.	1.0	46
143	Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. Translational Respiratory Medicine, 2014, 2, 2.	3.8	23
144	Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1203-1213.	0.9	17

#	ARTICLE	IF	CITATIONS
145	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-“small cell lung cancer: Comparison with histological assessment. <i>Cancer Cytopathology</i> , 2014, 122, 445-453.	1.4	40
146	A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 2156-2162.	0.6	26
147	Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series. <i>Clinical Lung Cancer</i> , 2014, 15, 470-474.	1.1	13
148	Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2014, 15, 411-417.e4.	1.1	32
149	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1783-1793.	1.2	8
150	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014, 5, 3518.	5.8	239
151	Treatment of Advanced Non-“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014, 15, 173-181.	1.1	56
152	Management of Italian Patients With Advanced Non-“Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study. <i>Clinical Lung Cancer</i> , 2014, 15, 338-345.e1.	1.1	7
153	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet, The</i> , 2014, 384, 665-673.	6.3	1,068
154	First-Line Crizotinib Vs Pemetrexed + Cisplatin/Carboplatin in Asian Patients with Advanced Alk+ Nsclc in Profile 1014. <i>Annals of Oncology</i> , 2014, 25, v2.	0.6	3
155	The Role of ERBB Family Blockade in NSCLC. <i>The Journal of Oncopathology</i> , 2014, 2, 51-58.	0.1	0
156	Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11035-11035.	0.8	4
157	First-line crizotinib versus pemetrexed-“cisplatin or pemetrexed-“carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). <i>Journal of Clinical Oncology</i> , 2014, 32, 8002-8002.	0.8	44
158	The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?. <i>Current Drug Targets</i> , 2014, 15, 1284-1292.	1.0	10
159	The Human Epidermal Growth Factor Receptor (HER) Family: Structure and Function. , 2014, , 7-17.		0
160	EGFR-Targeted Therapies in Non-small Cell Lung Cancer. , 2014, , 31-66.		0
161	Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11056-11056.	0.8	0
162	Targeting MET in NSCLC: looking for a needle in a haystack. <i>Translational Lung Cancer Research</i> , 2014, 3, 389-91.	1.3	8

#	ARTICLE	IF	CITATIONS
163	Ceritinib for the treatment of non-small cell lung cancer. <i>Drugs of Today</i> , 2014, 50, 465.	0.7	2
164	Targeted therapy for NSCLC with driver mutations. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1401-1412.	1.4	42
165	Strategies for improving outcomes in NSCLC: A look to the future. <i>Lung Cancer</i> , 2013, 82, 375-382.	0.9	29
166	HER2 and lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1219-1228.	1.1	63
167	Randomized phase III study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. <i>BJU International</i> , 2013, 111, 44-52.	1.3	67
168	Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study. <i>Lung Cancer</i> , 2013, 82, 231-237.	0.9	83
169	Erlotinib in the first-line treatment of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 523-533.	1.1	17
170	Let-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features. <i>International Journal of Oncology</i> , 2013, 43, 765-774.	1.4	53
171	Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 130-136.	1.1	32
172	HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2013, 108, 668-675.	2.9	131
173	Rare mutations in non-small-cell lung cancer. <i>Future Oncology</i> , 2013, 9, 699-711.	1.1	23
174	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. <i>Journal of Thoracic Oncology</i> , 2013, 8, 373-384.	0.5	113
175	MET overexpression and gene amplification in NSCLC: a clinical perspective. <i>Lung Cancer: Targets and Therapy</i> , 2013, 4, 15.	1.3	9
176	Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. <i>Biologics: Targets and Therapy</i> , 2013, 7, 61.	3.0	34
177	Irreversible EGFR-TKIs: dreaming perfection. <i>Translational Lung Cancer Research</i> , 2013, 2, 40-9.	1.3	20
178	Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens. <i>Journal of Clinical Oncology</i> , 2013, 31, 11058-11058.	0.8	0
179	Micro-RNA signature differences in lung adenocarcinoma with specific driver alterations. <i>Journal of Clinical Oncology</i> , 2013, 31, 11066-11066.	0.8	0
180	The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1. <i>Journal of Clinical Pathology</i> , 2012, 65, 1-7.	1.0	34

#	ARTICLE	IF	CITATIONS
181	Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2012, 23, 670-677.	0.6	44
182	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. <i>Journal of Clinical Pathology</i> , 2012, 65, 218-223.	1.0	35
183	Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. <i>Annals of Oncology</i> , 2012, 23, 388-394.	0.6	87
184	p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 520-527.	0.5	19
185	First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly "unfrail" patients with advanced non-small-cell lung cancer: a multicenter phase II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 2003-2008.	1.2	2
186	Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 4570-4579.	3.2	405
187	EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. <i>Cancer Treatment Reviews</i> , 2012, 38, 416-430.	3.4	114
188	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	9.4	1,186
189	Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Lung Cancer</i> , 2012, 76, 269-279.	0.9	24
190	Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer. <i>Drugs</i> , 2012, 72, 28-36.	4.9	61
191	Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. <i>British Journal of Cancer</i> , 2012, 107, 793-799.	2.9	109
192	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. , 2012, 2012, 1-8.		23
193	Emerging drugs for small cell lung cancer – an update. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 31-36.	1.0	20
194	Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 474-474.	0.8	3
195	MYC gene copy number (GCN) and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e21018-e21018.	0.8	0
196	Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?. <i>Journal of Thoracic Disease</i> , 2012, 4, 226-8.	0.6	2
197	EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMATION. <i>Translational Lung Cancer Research</i> , 2012, 1, 160-2.	1.3	0
198	Front-line therapy in lung cancer with mutations in EGFR. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 571-573.	12.5	15

#	ARTICLE	IF	CITATIONS
199	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. <i>Lung Cancer</i> , 2011, 71, 249-257.	0.9	113
200	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues. <i>Lung Cancer</i> , 2011, 72, 3-8.	0.9	43
201	Prospective Molecular Marker Analyses of <i>EGFR</i> and <i>KRAS</i> From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4113-4120.	0.8	280
202	Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2011, 6, 395-396.	0.5	44
203	Gefitinib for non-small-cell lung cancer treatment. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 987-996.	1.0	13
204	Genetic Activation of the <i>MET</i> Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4789-4795.	0.8	150
205	Is FISH floating or still swimming in the lung cancer ocean?. <i>Annals of Oncology</i> , 2011, 22, 493-499.	0.6	6
206	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. <i>Science Translational Medicine</i> , 2011, 3, 99ra86.	5.8	543
207	Abstract 3195: HMGA1 and HMGA2 over-expression in human lung carcinoma. , 2011, , .		0
208	Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1706-1713.	0.5	273
209	Impact of biomarkers on non-small cell lung cancer treatment. <i>Targeted Oncology</i> , 2010, 5, 5-17.	1.7	17
210	Consequences of targeted treatments for second-line therapy. <i>Annals of Oncology</i> , 2010, 21, vii234-vii240.	0.6	4
211	Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. <i>Annals of Oncology</i> , 2010, 21, 562-567.	0.6	70
212	Frequent and Focal <i>FGFR1</i> Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. <i>Science Translational Medicine</i> , 2010, 2, 62ra93.	5.8	761
213	Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens. <i>Oncologist</i> , 2010, 15, 1102-1112.	1.9	64
214	Clinical implications of MET gene copy number in lung cancer. <i>Future Oncology</i> , 2010, 6, 239-247.	1.1	50
215	Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature?. <i>Human Pathology</i> , 2010, 41, 614-615.	1.1	0
216	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2010, 11, 521-529.	5.1	1,158

#	ARTICLE	IF	CITATIONS
217	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , The, 2010, 11, 753-762.	5.1	1,915
218	Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events. , 2010, , .		0
219	Gemcitabine for the treatment of advanced nonsmall cell lung cancer. <i>OncoTargets and Therapy</i> , 2009, 2, 209.	1.0	15
220	Genetic Abnormalities of the <i>EGFR</i> Pathway in African American Patients With Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5620-5626.	0.8	85
221	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. <i>Annals of Oncology</i> , 2009, 20, 1674-1681.	0.6	147
222	EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. <i>Journal of Clinical Pathology</i> , 2009, 62, 970-977.	1.0	105
223	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2009, 20, 298-304.	0.6	286
224	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. <i>Oncogene</i> , 2009, 28, S32-S37.	2.6	246
225	Increased <i>MET</i> Gene Copy Number Negatively Affects Survival of Surgically Resected Non-“Small-Cell Lung Cancer Patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 1667-1674.	0.8	530
226	Emerging drugs for small-cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 591-606.	1.0	20
227	Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones. <i>Neoplasia</i> , 2009, 11, 1084-1092.	2.3	92
228	New targeted therapies for non-small-cell lung cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 335-350.	0.2	4
229	MYC and EIF3H Coamplification Significantly Improve Response and Survival of Non-small Cell Lung Cancer Patients (NSCLC) Treated with Gefitinib. <i>Journal of Thoracic Oncology</i> , 2009, 4, 472-478.	0.5	50
230	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. <i>Targeted Oncology</i> , 2008, 3, 173-186.	1.7	3
231	Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. <i>Cancer</i> , 2008, 112, 1555-1561.	2.0	89
232	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. <i>Annals of Oncology</i> , 2008, 19, 717-723.	0.6	243
233	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. <i>British Journal of Cancer</i> , 2008, 99, 83-89.	2.9	167
234	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , 2008, 99, 51-56.	2.9	107

#	ARTICLE	IF	CITATIONS
235	Lung cancer screening with spiral CT. <i>Lung Cancer</i> , 2008, 59, 355-363.	0.9	179
236	EGFR FISH versus mutation: Different tests, different end-points. <i>Lung Cancer</i> , 2008, 60, 160-165.	0.9	44
237	Primary pulmonary meningioma. <i>Lung Cancer</i> , 2008, 62, 401-407.	0.9	73
238	Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4253-4260.	0.8	220
239	Is gemcitabine cost effective in cancer treatment?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 239-249.	0.7	1
240	Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2007, 18, ix150-ix155.	0.6	12
241	Optimizing Anti-EGFR Strategies in Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 267-275.	0.2	0
242	Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Oncologist</i> , 2007, 12, 211-220.	1.9	44
243	EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, 423-429.	0.5	84
244	C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). <i>Journal of Thoracic Oncology</i> , 2007, 2, S359-S360.	0.5	5
245	M03-02: Molecular predictors for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): role of egfr gene amplification. <i>Journal of Thoracic Oncology</i> , 2007, 2, S156-S157.	0.5	1
246	Assessment of tumor response in malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2007, 33, 533-541.	3.4	56
247	Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 2248-2255.	0.8	218
248	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. <i>Annals of Oncology</i> , 2007, 18, 752-760.	0.6	257
249	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 183-191.	1.6	2
250	D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors. <i>Journal of Thoracic Oncology</i> , 2007, 2, S396.	0.5	1
251	Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S12-S14.	0.5	6
252	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. <i>Science</i> , 2007, 316, 1039-1043.	6.0	4,187

#	ARTICLE	IF	CITATIONS
253	Should every lung cancer patient be tested for EGFR mutation?. Expert Opinion on Therapeutic Targets, 2006, 10, 789-791.	1.5	1
254	A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer, 2006, 52, 319-325.	0.9	33
255	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 2006, 1, S13-S19.	0.5	71
256	Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). Reviews on Recent Clinical Trials, 2006, 1, 1-13.	0.4	44
257	Clinical experience with gefitinib: An update. Critical Reviews in Oncology/Hematology, 2006, 58, 31-45.	2.0	50
258	Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment, 2006, 95, 45-53.	1.1	33
259	Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 3078-3084.	3.2	97
260	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Annals of Oncology, 2006, 17, ii42-ii45.	0.6	28
261	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2006, 17, 1120-1127.	0.6	93
262	HER2 Mutation and Response to Trastuzumab Therapy in Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2006, 354, 2619-2621.	13.9	217
263	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 2006, 1, S13-S19.	0.5	106
264	Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. Journal of Thoracic Oncology, 2006, 1, S13-9.	0.5	34
265	Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. British Journal of Cancer, 2005, 93, 29-34.	2.9	28
266	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. British Journal of Cancer, 2005, 93, 1334-1340.	2.9	73
267	Erlotinib in Gliomas: Should Selection Be Based on EGFR and Akt Analyses?. Journal of the National Cancer Institute, 2005, 97, 868-869.	3.0	23
268	RESPONSE: Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 462-463.	3.0	1
269	Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 461-462.	3.0	3
270	Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5007-5018.	0.8	367

#	ARTICLE	IF	CITATIONS
271	Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 643-655.	3.0	1,517
272	Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3279-3287.	0.8	264
273	Role of gemcitabine in cancer therapy. <i>Future Oncology</i> , 2005, 1, 7-17.	1.1	288
274	Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. <i>Annals of Oncology</i> , 2004, 15, 1042-1047.	0.6	322
275	Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1133-1141.	3.0	367
276	Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6006-6012.	3.2	40
277	Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1795-1795.	3.0	0
278	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). <i>British Journal of Cancer</i> , 2004, 90, 82-86.	2.9	52
279	Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 31-35.	2.9	66
280	Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma. <i>Cancer</i> , 2003, 98, 128-134.	2.0	42
281	ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. <i>British Journal of Cancer</i> , 2003, 89, 246-247.	2.9	44
282	Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2003, 41, 227-231.	0.9	116
283	Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 42, 355-361.	0.9	16
284	Gefitinib in Pretreated Non-Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC. <i>Journal of Clinical Oncology</i> , 2003, 21, 2658-2663.	0.8	213
285	Emerging drugs for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 179-192.	1.0	13
286	Gemcitabine in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 745-753.	0.9	9
287	Present and future treatment of advanced non-small cell lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 9-16.	0.8	19
288	Multimodality therapy for non-small cell lung cancer (NSCLC): ongoing Italian experiences in the adjuvant and neoadjuvant settings. <i>Lung Cancer</i> , 2001, 34, 45-47.	0.9	0

#	ARTICLE	IF	CITATIONS
289	Induction treatments in marginally operable non-small cell lung cancer. <i>European Journal of Cancer</i> , 1999, 35, S386.	1.3	0
290	Glutamine supplementation in cancer patients receiving chemotherapy: A double-blind randomized study. <i>Nutrition</i> , 1997, 13, 748-751.	1.1	68
291	Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2546-2551.	0.8	126
292	Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2613-2619.	0.8	43
293	Activity of Formestane in de novo Tamoxifen-Resistant Patients with Metastatic Breast Cancer. <i>Oncology</i> , 1995, 52, 454-457.	0.9	6